Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of rabies mRNA vaccine CV7202 in healthy adults
NCT03713086Phase 1Completed
- Sponsor
- CureVac
- Start
- Oct 2018
- Primary completion
- Nov 2021
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label trial of CV7202 in rabies (4 arms), sponsored by CureVac. Primary endpoints: Number of Participants Who Experienced a Local Solicited Adverse Event (AE) Post Dose 1, Number of Participants With Grade 0, 1, 2 and 3 Local Solicited AEs Post Dose 1 and 12 more. Started Oct 2018; status: completed.
02
Drugs
CV7202
03
Conditions
rabies
Beyond the preview
Go deeper on NCT03713086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03713086.